We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Dariush Mozaffarian

Dariush Mozaffarian MD, DrPH

Dean, Friedman School of Nutrition Science & Policy, Tufts University, Jean Mayer Professor of Nutrition and Medicine, Boston, MA
Dr. Mozaffarian reports consulting fees from Acasti Pharma for serving as the principal investigator of TRILOGY, two phase 3 trials of omega-3 fatty acids to reduce hypertriglyceridemia; and from the Cleveland Clinic Foundation for serving on the Executive Committee of the STRENGTH trial, a large randomized controlled trial of omega-3 fatty acids to reduce cardiovascular events in patients with hypertriglyceridemia. The author also reports ad hoc honoraria or consulting from GOED, DSM, Nutrition Impact, Pollock Communications, Bunge, and Indigo Agriculture; royalties from UpToDate for online medical chapters; scientific advisory board, Omada Health and Elysium Health; and research funding from the National Institutes of Health and the Gates Foundation; all outside the present work.